Collagen crosslinking increases the biomechanical strength of the human cornea by about 300% by the combined action of a photosensitizing substance (riboflavin) and ultraviolet A (UVA) light from a solid-state source. The treatment creates additional chemical bonds inside the anterior 200 to 300 microns of the corneal stroma by means of photopolymerization. There is minimal exposure to the surrounding structures of the eye. Collagen crosslinking increases the resistance to pepsin digestion by enhancing corneal anticollagenase activity and induces a thicker collagen fiber diameter. Confocal microscopy studies have also shown apoptosis of keratocytes in the anterior and intermediate stroma followed by a gradual keratocytes repopulation.

The object of this review is to illustrate keratectasia after LASIK and its treatment by collagen corneal crosslinking.

**LASIK**

**Technique**

An important part of population suffers from myopia and astigmatism, conditions that reduce visual acuity if not corrected with glasses. Nowadays, the introduction of excimer laser allowed the resolution of refractive error by corneal surgical techniques (LASIK, PRK, etc.).

LASIK involves the formation of lamellar corneal flap and the remodeling of the underlying stromal tissue. The patient undergoing LASIK surgery, is medicated with topical anesthetic (e.g. oxybuprocaine), topical antibiotic (e.g. ciprofloxacin) and topical anti-inflammatory drops (e.g. dexamethasone). The patient is positioned on the bed, a microkeratome or a femtosecond LASIK flap creates a corneal flap, an excimer laser remodels the corneal stroma in order to reduce the refractive error and then the corneal flap is repositioned. Femtosecond LASIK, compared with microkeratome, seems to show a better refractive outcome; in fact, the use of microkeratome resulted in a greater aberration values than femtosecond laser.

**Corneal Ectasia after LASIK**

Thin-flap LASIK was conceived to reduce the thickness of the flap and consequently preserving the cornea stroma. Thin-flap LASIK is related to the possibility to increase the ability to treat higher myopia, and the use of thin-flap suggests to reduce the incidence of post-LASIK ectasia.
Post-LASIK ectasia is one of the most insidious complication and, in 2008, Randleman et al developed an ectasia risk score system, which analyzed five criteria. The criteria analyzed were: age of patients, spheric equivalent of refractive error, residual stromal bed thickness, corneal thickness and abnormal corneal topography. This score is a useful tool, with a sensitivity of 91% and specificity of 92%.²¹ Comaiish and Lawless investigated the pathophysiology of progressive post-LASIK keratectasia (PPLK), considering this complication, linked to dynamic and static fatigue effects evaluating also the possibility subclinical inflammation that can lead to an activation of metalloproteinases and collagenases, resulting in a modification collagen fibers. These proteolytic modifications are studied in different pathologies in particular in keratoconus that shares with PPLK several aspects.²² Though in post-LASIK ectasia Meghpara et al did not find any classic pathognomonic signs of keratoconus, like the Bowman layer disruption, but found the presence of thinning of collagen fibrils and decreased interfibrillar distance.²³

A high amount of tissue removed by the refractive procedure was associated with greater corneal biomechanical destabilization, increased corneal steepening and a worse prognosis.²⁴ Recently, we referred that the incidence of post-LASIK corneal ectasia was 0.57% and the onset was about 2.5 years from operation. The patients were classified according to Randleman Ectasia Risk Score System, evidencing that the most important risk factors were a high spherical refractive error and a reduced corneal stromal bed.²⁵ Binder et al compared different studies that reported the incidence of corneal ectasia post-LASIK treatment. The incidence reported was between 0.01 and 0.9 %. The authors referred several papers that reported cases of post-LASIK ectasia in keratoconus or pellucid marginal degeneration where there was not a well documented preoperative and postoperative study of corneal thickness, making impossible to know the residual corneal thickness. This is very important because post-LASIK residual corneal thickness is the most important factor influencing the ectasia onset.²⁶ Binder et al clearly explained that the clinical examination at slit lamp permits to recognize keratoconus. Corneal topography is a valid exam to find the presence of forme fruste keratoconus before LASIK, and it is really important because forme fruste keratoconus could develop a clinical evident keratoconus. LASIK should be avoided in patients who show the blue-spot that is connected to possibility to develop pellucid marginal degeneration.²⁷

**Treatment of Keratectasia after LASIK**

Although several risk factors for keratectasia after LASIK have been identified and screening techniques continue to improve, post-LASIK keratectasia still occurs.²⁷ Invasive treatment of keratectasia include lamellar or penetrating keratoplasty: Kucumen et al described four patients who developed corneal ectasia after LASIK and required penetrating keratoplasty (PKP) and they confirmed that PKP is successful in treating severe corneal ectasia after LASIK, but the treatment of the patient may last for the rest of his or her life owing to potential postoperative complications.²⁸

However, after the introduction and successful use of deep anterior lamellar keratoplasty (DALK), PKP is no longer the best choice in these cases. Deep anterior lamellar keratoplasty has the advantages of being an extraocular procedure that treats abnormal stroma and leaves the healthy endothelial cells in place.²⁹,³⁰ Results in several studies³¹-³³ indicate the visual outcomes after DALK are comparable to those after PKP in cases of keratoconus. In addition, recent studies³⁴-³⁶ report promising results of DALK in cases of iatrogenic ectasia.

There are also minimally invasive techniques. A case of transient post-LASIK keratectasia associated with a marked elevation of intraocular pressure (IOP), where the keratectasia subsided promptly after IOP normalization treated with an intravenous administration of mannitol, has previously been reported.³⁷

The use of intrastromal corneal ring segments (Intacs) for post-LASIK ectasia has been previously reported with positive results.³⁸-⁴⁰ Pokroy et al have used implantation of Intacs post-LASIK in five patients. Although the Intacs incision passed through the LASIK flap and the vacuum-centering guide acted at the center of the flap, the flap was not disrupted in any case. They had no superficial corneal buttonholing as we were careful to dissect the entire length of the Intacs channel at least 370 µm deep, no segment extrusion as the proximal end of the segment was implanted at least 1.0 mm in the channel. Ectatic corneas are thinner, less rigid and less symmetric than normal corneas, making buttonholing and segment extrusion more likely if the above precautions are not taken.⁴⁰

Treatment of post-LASIK ectasia with crosslinking procedures has also shown promise.¹⁰,⁴¹

**Crosslinking**

Corneal collagen crosslinking (CXL) is a relatively new technique used for the stabilization of ectatic disorders.⁴²,⁴³ The objective of this technique is the increase of corneal strength and stability by inducing cross links at the corneal stroma using riboflavin as a photosensitizer and UVA to increase the formation of intra- and interfibrillar covalent bonds by photosensitized oxidation. Today, CXL with deepithelialization is limited to eyes with a corneal thickness
of at least 400 μm due to concerns about the cytotoxic effect on the endothelium, crystalline lens and other intraocular tissues.\textsuperscript{45}

Corneal crosslinking is an outpatient procedure generally performed with topical anesthesia. The epithelial cell layer is first removed, often using a blunt spatula, in a 9.0 mm diameter under sterile conditions. Then a topical 0.1% riboflavin (vitamin B\textsubscript{2}) solution is applied every 3 to 5 minutes for 15 to 30 minutes to ensure that the corneal stroma is fully penetrated. A solid-state UVA light source with a wavelength of 370 nm (maximum absorption of riboflavin) and an irradiance of 3 mW/cm\textsuperscript{2} is used to irradiate the central cornea. Following treatment, a soft bandage lens is applied and prescriptions given for oral pain medications, preservative-free tears, anti-inflammatory drops and antibiotic eye drops. Patients are recalled at 1 week post-procedure to evaluate re-epithelialization, with subsequent follow-up appointments to monitor status.

Riboflavin acts as a photosensitizer and has an absorption peak for UVA wavelength of approximately 370 microns.\textsuperscript{43} Riboflavin-saturated cornea exposed to UVA radiation at this wavelength fluoresces and is excited into a triplet state with subsequent generation of singlet oxygen (mainly) and superoxide anion radicals. The reactive oxygen species leads to the formation of covalent bonds bridging amino acids of collagen fibrils by oxidative process dependent on the presence of O\textsubscript{2} and enhanced by deuterium oxide. The increased bonding in the corneal stromal layer leads to an increased ‘stiffness’ of the cornea.

The first reports of clinical experience with this treatment for corneal melting appeared in 2000.\textsuperscript{46} In 2003, a halt in the progression of the keratectasia has been highlighted after CXL in eyes with progressive keratoconus.\textsuperscript{43} The authors found a decrease in maximum keratometry readings and an improvement in visual acuity during the first postoperative years. This finding was confirmed in 2006 by Caporossi et al\textsuperscript{47} in a 3-month follow-up after CXL as well as in 2008 by Wittig-Silva et al\textsuperscript{48} and in 2009 by Koller et al\textsuperscript{49} in controlled prospective studies with a completed 1-year follow-up. Other applications of CXL include iatrogenic keratectasia in pellucid marginal degeneration,\textsuperscript{50} after LASIK and PRK\textsuperscript{51-53} and infectious keratitis.\textsuperscript{54} All these studies found CXL to be efficacious in stopping the progression of keratectasia.

Crosslinking and Keratoconus

Keratoconus is a slowly progressive, noninflammatory corneal dystrophy characterized by changes in corneal collagen structure and organization.\textsuperscript{55-57} A reduced number of collagen cross-links and a pepsin digestion higher than normal induce an overall structural weakness of the corneal tissue, resulting in a stiffness that is only 60% that of the normal cornea.\textsuperscript{58} Decreased mechanical corneal stability plays an important role in the progressive protrusion of the keratoconic cornea, resulting in mild to marked impairment of visual acuity owing to irregular astigmatism, progressive myopia, corneal thinning and central corneal scarring.\textsuperscript{59} Keratoconus does not involve only the anterior surface of the cornea and its thickness. Rather, it affects all anterior segment parameters.\textsuperscript{60}

Currently, available treatments for keratoconus (rigid contact lens, lamellar keratoplasty, corneal rings) largely involve interventions which are done for tectonic, optical or refractive reasons.\textsuperscript{61} Unfortunately, none of these options treat the underlying cause of ectasia and, therefore, cannot stop the progression of keratoconus. In recent years, basic laboratory studies and subsequent clinical studies have demonstrated stiffening of the cornea with use of UVA light and riboflavin solution as a photosensitizer-initiated corneal collagen crosslinking with no loss in corneal transparency. Vinciguerra et al have demonstrated a significant decrease in total corneal volume and anterior chamber depth (ACD) 12 months after CXL.\textsuperscript{62} Crosslinking induces the creation of new bonds between the collagen fibers.\textsuperscript{11,42,43,63,64} The reduction of ACD at the cone apex matched the maximum reduction in elevation and the increased packing of collagen fibers, as demonstrated by Mencucci et al.\textsuperscript{65} The results of the Siena Eye Cross Study showed a long-term stability of keratoconus after crosslinking without relevant side effects on 44 eyes after 48 months of minimum follow-up: the uncorrected visual acuity and best spectacle-corrected visual acuity improvements were supported by clinical, topographic and wavefront modifications induced by the treatment.\textsuperscript{66} Mazzotta et al have studied ultrastructural stromal modifications after riboflavin-UVA-induced cross-linking of corneal collagen in 10 patients with progressive keratoconus and they have showed a reduction in anterior and intermediate stromal keratocytes followed by gradual repopulation confirmed directly \textit{in vivo} in humans by HRT II-RCM confocal microscopy.\textsuperscript{14}

Nowadays, CXL is limited to eyes with a corneal thickness of at least 400 μm due to concerns about the cytotoxic effect on the endothelium, crystalline lens and other intraocular tissues.\textsuperscript{43,45} This threshold has limited its performance in eyes with advanced stages of corneal ectasia. Transepithelial CXL,\textsuperscript{67} CXL with customized pachymetric-guided epithelial debridement to preserve the epithelium in thinner corneal regions,\textsuperscript{68} and the concept of iatrogenic corneal swelling before CXL application\textsuperscript{69} have each been developed as alternative techniques for thin corneas with thinnest pachymetry values of less than 400 μm.\textsuperscript{70}
Crosslinking and Keratectasia after LASIK

Corneal ectasia is a serious vision-threatening complication of LASIK. It is associated with progressive corneal steepening, an increase in myopia and astigmatism, and decrease in uncorrected visual acuity. There are several parameters, such as high myopic corrections, thin corneas and residual corneal bed thickness less than 250 μm, which represent major risk factors for this condition. Clearly, prevention of induced keratectasia is the best strategy and special emphasis should be placed on recognizing corneas that are at risk before surgery. Reduction of corneal biomechanical strength seems to be an essential element in the chain of event leading to iatrogenic keratectasia after LASIK. The anterior stroma confers more biomechanical strength to the cornea than the posterior stroma, and it is the anterior stroma that is weakened by flap generation and...
Corneal Collagen Crosslinking for Keratectasia after Laser in situ Keratomileusis: A Review of the Literature

et al\textsuperscript{76} in a previous study proposed a two step procedure of corneal crosslinking followed by PRK with a 1 year interval. According to this study, documentation of the stability for at least 1 year is essential before proceeding with the laser treatment. This approach has several limitations. The stiffened crosslinked corneal tissue is partly removed by the consequential PRK procedure. There is no control over the efficacy of this approach, since the corneal ablation rate could be different in cross linked corneas as compared to virgin corneas and this could lead to unpredictable refractive results. Lastly, there is an increased possibility of post-PRK haze formation since it is known that, after CXL, the anterior stromal is repopulated by new keratocytes after 6 months.\textsuperscript{16,77} In a prospective pilot interventional case series, Celik et al\textsuperscript{78} performed simultaneous CXL and LASIK to prevent ectasia and found no occurrence of significant refractive change or side effects during the 1-year follow-up. The authors conclude that this procedure appears to be a promising modality for future applications to prevent corneal ectasia after LASIK treatment. Kymionis et al described a post-LASIK patient who developed diffuse lamellar keratitis (DLK) after corneal crosslinking treatment which was successfully treated with intensive topical corticosteroids.\textsuperscript{79} Several crosslinking factors, such as epithelium removal and UV A light, could trigger DLK. Epithelium removal has been related to epithelium-derived cytokines, such as interleukin-1, that stimulate keratocytes to produce chemokines which attract inflammatory cells.\textsuperscript{80}

Moreover, prophylactic collagen crosslinking for high-risk LASIK cases\textsuperscript{81} and combined to PRK to correct residual refractive error in patients previously submitted to lamellar keratoplasty for keratoconus\textsuperscript{82} was demonstrated to be a safe and effective adjunctive treatment for refractive regression and potential ectasia. In fact, prophylactic crosslinking may offer a significant benefit in patients with personal history of keratoconus and/or in the correction of high myopia and hyperopia.

CONCLUSION

As noted earlier, it is well known that LASIK reduces the biomechanical stability of the cornea by intersecting with structural lamellae in the anterior cornea and, of course, by removing some of the structural lamellae in lieu of ablation. Riboflavin-UVA corneal crosslinking increased the biomechanical and biochemical stability of the cornea and may thus be a therapeutic means to arrest or reverse the progression of LASIK-induced keratectasia. This application may be viewed as prophylactic customization of the biomechanical behavior of corneal collagen.
REFERENCES

Corneal Collagen Crosslinking for Keratectasia after Laser in situ Keratomileusis: A Review of the Literature


ABOUT THE AUTHORS

Leopoldo Spadea
Associate Clinical Professor of Ophthalmology, Department of Medical-Surgical Sciences and Biotechnology, La Sapienza University of Rome, Latina, Italy
Correspondence Address: Via Benozzo Gozzoli 34, 00142 Rome Italy, Phone/Fax: +39065193220, e-mail: leopoldo.spadea@uniromal.it

Francesca Verboschi
Member in Training, Department of Medical-Surgical Sciences and Biotechnology, La Sapienza University of Rome, Latina, Italy

Stefano Valente
Member in Training, Department of Medical-Surgical Sciences and Biotechnology, La Sapienza University of Rome, Latina, Italy

Enzo Maria Vingolo
Aggregate Clinical Professor of Ophthalmology, Department of Medical-Surgical Sciences and Biotechnology, La Sapienza University of Rome, Latina, Italy